Suppr超能文献

2021-2022 年流感季美国因流感住院或死亡的<18 岁以下儿童和青少年中 SARS-CoV-2 和流感合并感染的流行率及临床特征。

Prevalence of SARS-CoV-2 and Influenza Coinfection and Clinical Characteristics Among Children and Adolescents Aged <18 Years Who Were Hospitalized or Died with Influenza - United States, 2021-22 Influenza Season.

出版信息

MMWR Morb Mortal Wkly Rep. 2022 Dec 16;71(50):1589-1596. doi: 10.15585/mmwr.mm7150a4.

Abstract

The 2022-23 influenza season shows an early rise in pediatric influenza-associated hospitalizations (1). SARS-CoV-2 viruses also continue to circulate (2). The current influenza season is the first with substantial co-circulation of influenza viruses and SARS-CoV-2 (3). Although both seasonal influenza viruses and SARS-CoV-2 can contribute to substantial pediatric morbidity (3-5), whether coinfection increases disease severity compared with that associated with infection with one virus alone is unknown. This report describes characteristics and prevalence of laboratory-confirmed influenza virus and SARS-CoV-2 coinfections among patients aged <18 years who had been hospitalized or died with influenza as reported to three CDC surveillance platforms during the 2021-22 influenza season. Data from two Respiratory Virus Hospitalizations Surveillance Network (RESP-NET) platforms (October 1, 2021-April 30, 2022), and notifiable pediatric deaths associated with influenza virus and SARS-CoV-2 coinfection (October 3, 2021-October 1, 2022)** were analyzed. SARS-CoV-2 coinfections occurred in 6% (32 of 575) of pediatric influenza-associated hospitalizations and in 16% (seven of 44) of pediatric influenza-associated deaths. Compared with patients without coinfection, a higher proportion of those hospitalized with coinfection received invasive mechanical ventilation (4% versus 13%; p = 0.03) and bilevel positive airway pressure or continuous positive airway pressure (BiPAP/CPAP) (6% versus 16%; p = 0.05). Among seven coinfected patients who died, none had completed influenza vaccination, and only one received influenza antivirals. To help prevent severe outcomes, clinicians should follow recommended respiratory virus testing algorithms to guide treatment decisions and consider early antiviral treatment initiation for pediatric patients with suspected or confirmed influenza, including those with SARS-CoV-2 coinfection who are hospitalized or at increased risk for severe illness. The public and parents should adopt prevention strategies including considering wearing well-fitted, high-quality masks when respiratory virus circulation is high and staying up-to-date with recommended influenza and COVID-19 vaccinations for persons aged ≥6 months.

摘要

2022-23 年流感季节显示儿科流感相关住院率(1)早期上升。SARS-CoV-2 病毒也在继续传播(2)。目前的流感季节是第一个同时存在大量流感病毒和 SARS-CoV-2 (3)的季节。虽然季节性流感病毒和 SARS-CoV-2 都可能导致大量儿科发病率(3-5),但与单独感染一种病毒相比,合并感染是否会增加疾病严重程度尚不清楚。本报告描述了在 2021-22 年流感季节期间,向三个 CDC 监测平台报告的年龄<18 岁的流感住院或死亡患者中,实验室确诊的流感病毒和 SARS-CoV-2 合并感染的特征和流行率。来自两个呼吸道病毒住院监测网络(RESP-NET)平台的数据(2021 年 10 月 1 日至 2022 年 4 月 30 日),以及与流感病毒和 SARS-CoV-2 合并感染相关的可报告儿科死亡(2021 年 10 月 3 日至 2022 年 10 月 1 日)**进行了分析。SARS-CoV-2 合并感染发生在儿科流感相关住院率的 6%(575 例中的 32 例)和儿科流感相关死亡的 16%(44 例中的 7 例)。与未合并感染的患者相比,合并感染住院患者接受有创机械通气(4%对 13%;p=0.03)和双相气道正压通气或持续气道正压通气(BiPAP/CPAP)(6%对 16%;p=0.05)的比例更高。在 7 例合并感染死亡的患者中,均未完成流感疫苗接种,仅 1 例接受了流感抗病毒治疗。为了帮助预防严重后果,临床医生应遵循推荐的呼吸道病毒检测算法,以指导治疗决策,并考虑对疑似或确诊流感的儿科患者尽早开始抗病毒治疗,包括合并 SARS-CoV-2 感染且住院或有重症疾病风险增加的患者。公众和家长应采取预防策略,包括在呼吸道病毒传播高时考虑佩戴贴合良好、高质量的口罩,并为年龄≥6 个月的人群及时接种推荐的流感和 COVID-19 疫苗。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/09e0/9762905/b2ee9668580d/mm7150a4-F.jpg

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验